By Kyle Morris

Shares in Genedrive PLC rose 15% on Wednesday after the company said that it has begun the process for regulatory approval for its MT-RNR1 ID Kit with the U.S. Food and Drug Administration.

The molecular-diagnostics company said the MT-RNR1 assay is a rapid point-of-care test to screen infants in urgent care for a genetic variant that could cause life-long hearing loss when carriers are given certain antibiotics.

Shares in Genedrive at 0721 GMT were up 1.60 pence at 12.60 pence.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

October 05, 2022 03:38 ET (07:38 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Genedrive Charts.
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Genedrive Charts.